Skip to main content
AMGN
NASDAQ Life Sciences

Amgen Boosts MariTide Weight-Loss Drug Program, Reports 4% Q1 Sales Growth

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$339.25
Mkt Cap
$186.866B
52W Low
$261.43
52W High
$391.29
52W Position info
30% above low
Off High info
13% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AMGN sits 30% above its 52-week low of $261.43.

Summary

Amgen reported a 4% rise in first-quarter product sales, reaching $8.6 billion, with adjusted earnings per share of $5.15, surpassing analyst expectations. More significantly, the company announced a substantial broadening of its development program for the experimental weight-loss drug MariTide, initiating new studies including a trial for patients switching from weekly GLP-1s and advancing Phase 3 trials across various obesity-related conditions. This strategic expansion of the MariTide program is a highly material update, signaling Amgen's increased commitment to a potentially transformative asset in the high-growth weight-loss market. While Q1 financial results were largely covered by earlier news, the detailed pipeline update provides new, forward-looking information. Investors will now closely track MariTide's clinical progress and future regulatory milestones as a key driver for Amgen's long-term growth.

At the time of this announcement, AMGN was trading at $339.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $186.9B. The 52-week trading range was $261.43 to $391.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $461.67 info
Change: -$15.73 (-3%) info
Market Cap: $251.648B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $461.67 info
Change: -$3.25 (-0.70%) info
Market Cap: $251.648B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $461.67 info
Change: -$1.33 (-0.29%) info
Market Cap: $251.648B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $461.67 info
Change: +$1.10 (+0.24%) info
Market Cap: $251.648B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $461.67 info
Change: +$12.88 (+3%) info
Market Cap: $251.648B info